186P - Antiangiogenic therapy using bevacizumab in patients older than 75 years old with stage IV non-squamous non small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Geriatric Oncology
Non-Small Cell Lung Cancer
Biological Therapy
Presenter Edgardo Santos
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors E.S. Santos1, L.D.C. Castillero2
  • 1Medicine-oncology, Eugene M. & Christine E. Lynn Cancer Institute, 33486 - Boca Raton/US
  • 2School Of Medicine, Universidad Nacional de Panama, Panama/PA



Two retrospective studies have analyzed the effect of bevacizumab (Bev) in patients (pts) with metastatic NSq-NSCLC stratified by age. First analysis was from ECOG 4599 (pts  70 years old) and second analysis was a pooled analysis between ECOG 4599 and PointBreak studies. In the later, pts were grouped by age: 75 years old. There were more adverse events (AEs) in pts  75 years old in the C/P/Bev group vs C/P alone.


Using our electronic database, we used three variables: lung cancer, >75 years old, and Bev. In the last 12 months, we found 15 pts with these characteristics. Three were eliminated from the final analysis as 2 of them have 2 primaries (lung/rectal cancer and lung/ovarian cancer) and other pt received Bev different from frontline therapy. We analyzed safety and tolerability as well as number of Bev cycles given to these cohort.


Nine pts received C/P/Bev and 3 pts received C/Pem/Bev followed by maintenance (MTX) Bev. Median age was 77 years old (range, 75–82); 9 (75%) pts were female; all pts had adenocarcinoma histology. Most common AEs were: fatigue (n = 4), vomiting (n = 2), and diarrhea (n = 2). Only one pt stopped Bev due to SAEs (hypertensive crisis); no embolic events, nephrotic syndrome, gastrointestinal perforation, fistula perforation, RPLS, and serious hemorrhage were found. Median cycles of MTX Bev was 4.5 (range, 0–28); median total of Bev cycles including induction was 9.5 (range, 1–32). Median progression-free survival (PFS) was 7.1 months.


In our 12 pts older than 75 years old, we did not find major SAEs secondary to Bev but 1 pt. Our pts had good ECOG PS and 8 pts (75%) had 1 comorbid condition. Median PFS was similar to that reported in the literature when Bev has been combined with platinum-based doublet followed by MTX. With a detailed clinical history and careful assessment, our experience indicates that Bev can be offered to elderly pts older than 75 years old.

Clinical trial identification


Legal entity responsible for the study

Lynn Cancer Institute Research Department


Lynn Cancer Institute Research Department


E.S. Santos: Speaker Bureau: Genentech, Lilly US Oncology. All other authors have declared no conflicts of interest.